Living Longer Isn't the Same as Living Better

Saw a headline yesterday that stopped me mid-scroll: an AI-developed drug appeared to make patients biologically younger in a clinical trial. Mid-stage, small sample, plenty of caveats buried in paragraph four, but still. That’s a hell of a sentence to read on a Tuesday.

My first reaction was the same one I get whenever a longevity story pops up: genuine fascination, followed almost immediately by a low hum of dread. Both feelings are legitimate and I’m not going to pretend one cancels the other out.

The fascination part is easy to explain. I’m someone who reads about telomeres and senescent cells for fun, in the same way I read about black holes or the Bronze Age collapse. The idea that we might be able to nudge the ageing process, even slightly, even in a hundred trial patients who’ll be followed up for years yet, is genuinely one of the more interesting things happening in science right now. If it holds up. That “if” is doing a lot of work in that sentence.

The dread part came from the comments, and it wasn’t really about the drug at all. It was about who gets to grow old slower. One person put it bluntly: this will only be for the rich, so they can control us longer. Another reckoned the whole thing is really just a longer runway to keep squeezing labour out of us before retirement. I don’t think that’s a fringe cynical take, I think it’s the first thing most people’s gut says when they hear “life extension,” and for good reason. We’ve watched this movie before. New medical technology arrives, it’s miraculous, and then it turns out miracles have a price tag that scales with your postcode.

There’s a real tension here and I’m not going to pretend I’ve resolved it. On one hand, if a treatment genuinely keeps people healthier for longer, that’s not nothing, that’s fewer years of your knees giving out, fewer years watching your parents fade before the actual end. On the other hand, “healthier for longer” in a world that still ties healthcare to income and ties income to work is not automatically a gift. It can just as easily become an obligation. Someone in the thread joked about still doing rounds at 103. It got a laugh, but it’s also just a description of how this could actually go if nothing else changes.

I think about my own father-in-law, who worked in a factory in Dandenong for close to forty years and retired with a body that had clearly paid rent the whole way. He got maybe a decade of actually enjoying being retired before things started going downhill. If you’d offered him a drug at sixty that meant he could keep working until eighty, he would have told you exactly where to put it, and he’d have been right to. Longevity science aimed at the wrong end of the problem, extending the working years rather than the free ones, isn’t progress. It’s just a longer sentence.

None of this is really the fault of the researchers. Somebody in the trial team is presumably just trying to understand cellular ageing, and good luck to them, that’s hard and valuable work regardless of what a headline writer does with it afterwards. The AI angle got a fair bit of grief in the comments too, people assuming it’s a marketing beat-up because “AI-developed” sells better than “identified via a large computational screening process,” which is what it probably actually means. Fair scepticism. A lot of “AI did this” framing lately is doing PR work for AI companies more than it’s informing anyone about the science. Doesn’t mean the underlying result is fake, just means the packaging deserves a raised eyebrow.

Where I land, for what it’s worth: the science is worth being curious about, and the social arrangement around it is worth being suspicious of, and those two things aren’t in conflict. We’re allowed to be excited about what a treatment might do to a cell and simultaneously insist that if it works, it needs to be available to more than the people who can already afford good health outcomes anyway. That’s not a radical position, it’s just the same argument we’ve had about every major medical advance since insulin. We keep having it because we keep needing to.

I don’t know how this particular drug plays out. Mid-stage trials fail more often than they succeed, and “biologically younger” is a slippery thing to measure in the first place. But I’d rather have the conversation now, messy and half-informed, than wait until it’s a finished product with a price list and a waiting list a mile long for anyone without private health cover.